CEO
Invea Therapeutics
This biotechnology company develops oral small molecule therapeutics for immune-mediated inflammatory diseases (IMIDs). They utilize artificial intelligence and machine learning to decode the underlying mechanisms driving inflammation. The focus is on creating safe and effective product candidates to treat chronic IMIDs by targeting pathways like mast cell and inflammasome biology.
- Artificial Intelligence
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$9.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$2.1M across 3 disclosed rounds
$300K · Convertible Note
Announced Apr 2025
Disclosed cumulative: $2.1M
3/3
Reported total $9.5M
Incomplete round history. $7.4M of the $9.5M reported total isn’t matched to a known round.
RoundDateAmountValuationInvestors
Founders
Product
Problem
Current treatment options for immune-mediated inflammatory diseases (IMIDs) like atopic dermatitis and chronic urticaria often provide limited effectiveness and can have significant side effects. A comprehensive understanding of the complex pathophysiological mechanisms driving immune-mediated inflammation is lacking, hindering the development of targeted therapies.
Solution
Invea Therapeutics is developing oral small molecule therapeutics for immune-mediated inflammatory diseases (IMIDs) by leveraging artificial intelligence (AI) and machine learning (ML) to decode the mechanisms of inflammation. The company utilizes InveniAI’s AlphaMeld Platform to mine data on genes, drugs, diseases, symptoms, and processes, creating IMID-focused networks to identify crucial relationships and cause-and-effect connections. This approach aims to identify and develop targeted therapies that address the underlying causes of chronic inflammation. Invea's lead program, INVA8001, is a selective inhibitor of chymase, a key mediator of mast cell-driven inflammation, while their second product candidate, INVA8003, targets apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) to modulate inflammasome activity.
Target Audience
The primary target audience includes patients suffering from chronic immune-mediated inflammatory diseases (IMIDs) such as atopic dermatitis, chronic urticaria, and prurigo nodularis, as well as pharmaceutical companies seeking innovative therapies for these conditions.
Features
- AI and ML-driven drug discovery platform for identifying novel therapeutic targets in IMIDs
- INVA8001: A highly selective, oral chymase inhibitor targeting mast cell-driven inflammation
- INVA8003: An oral inhibitor targeting ASC to modulate inflammasome activity
- Focus on developing oral small molecule therapies for improved patient convenience and compliance
- Target association network comprising thousands of potential targets, drugs, and IMIDs